Aperio Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Aperio Group’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$1.37M	Buy	6,218 +1,642	+36%	+$355K	﹤0.01%	1424
2020 Q3	$760K	Buy	4,576 +2,543	+125%	+$348K	﹤0.01%	1585
2020 Q2	$232K	Buy	+2,033	New	+$197K	﹤0.01%	2133
2020 Q1	–	Sell	-1,679	Closed	-$216K	–	2413
2019 Q4	$216K	Buy	+1,679	New	+$162K	﹤0.01%	2179
2019 Q3	–	Sell	-490	Closed	-$50K	–	2841
2019 Q2	$50K	Buy	+490	New	+$38.1K	﹤0.01%	2533

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Aperio Group's MRTX Position: Q4 2020 in Review

Aperio Group increased its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 36% in Q4 2020, buying an estimated $355K and bringing the position to 6,218 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #1424.

Aperio Group first reported a position in MRTX in Q2 2019 and has held it in 5 quarters since. 284 funds tracked by Wall St. Rank hold MRTX as of Q4 2020.

Aperio Group held 6,218 shares of Mirati Therapeutics, Inc. Common Stock worth $1.37M as of Q4 2020.
Aperio Group bought 1,642 Mirati Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $355K.
Mirati Therapeutics, Inc. Common Stock made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1424 holding.
Aperio Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2019 and has held it in 5 quarters since.
284 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.